ER-100 Clinical Trial for Glaucoma: What We Know So Far and What to Expect
Another related condition, non-arteritic anterior ischemic optic neuropathy (NAION), causes sudden vision loss due to poor blood flow to the optic...
Deep research and expert guides on maintaining your visual health.
Another related condition, non-arteritic anterior ischemic optic neuropathy (NAION), causes sudden vision loss due to poor blood flow to the optic...
Life Biosciences is a biotechnology company that focuses on research and development aimed at slowing, reversing, or preventing the biological processes behind aging and age-related disease. The company explores a range of approaches, including drugs, gene-based therapies, and other biomedical strategies that target cellular pathways linked to longevity, cellular repair, and metabolic health. Their work often centers on translating ideas from basic aging biology into therapies that could improve healthspan—the years of life spent in good health—rather than simply extending lifespan. This kind of company matters because age is the biggest risk factor for many chronic diseases such as heart disease, neurodegeneration, and some cancers. If therapies can safely modify the underlying drivers of aging, they could reduce the burden of many illnesses at once and improve quality of life for older adults. At the same time, the field is high-risk and faces scientific, regulatory, and ethical challenges: promising lab results don’t always become safe, effective human treatments, and long-term effects must be carefully studied. Companies in this space often partner with academic labs, other biotech firms, and investors to fund development and clinical testing. For people following medical innovation, companies like this represent both hope for new ways to treat age-related problems and a reminder that rigorous testing is needed before new approaches become widely available.